NIDA-AACAP Resident Training Award in Substance Use Disorders, supported by the National Institute on Drug Abuse (NIDA) and sponsored by AACAP
The NIDA-AACAP Resident Training Award in Substance Use Disorders, supported by the National Institute on Drug Abuse (NIDA) and sponsored by AACAP, seeks to support the development of expertise in substance use disorders (SUD) through completion of a mentored experience and project focused on dissemination of SUD treatment research.
The goals of this award are:
- To promote and improve knowledge of evidence-based SUD treatment among health care providers;
- To promote dissemination of SUD research findings;
- To promote the adoption of evidence-based approaches in medical settings; and
- To facilitate the professional growth and development of future leaders in SUD management and research.
For early investigators, obtaining funding for training and mentored experiences is critical, but it is also the most difficult to secure. The NIDA-AACAP Resident Training Award provides up to one year of support to general and child and adolescent psychiatry residents to support training in dissemination of research. Through support from this program, the awardee(s) will:
- Engage in a mentored opportunity to learn about key areas of SUD and SUD treatment strategies through systematic literature review, attendance at conferences and workshops, and interaction with leading experts in the field.
This award cannot be used to conduct basic or clinical research studies or trials. Awardees are to develop and execute a plan designed to increase their knowledge of SUD and SUD treatment and complete a project aimed at improving the dissemination and/or adoption of SUD research findings. Secondary data analysis may be completed in pursuit of these aims, provided the project proposed is eligible for IRB exemption and has a dissemination/adoption focus. The award offers up to $10,000 for program support (award amount includes travel to AACAP's 68th Annual Meeting in Atlanta, GA, October 25-30, 2021; and travel to the NIDA Clinical Trials Network's Annual Meeting in Bethesda, MD, April 26-28, 2021) and $2,000 for a mentor stipend. (All awards are contingent upon the receipt of adequate funding support.)
PURPOSE OF THE AWARD
The purpose of this award is to:
- Provide the trainee with a mentored opportunity to learn about key areas of SUD and SUD treatment strategies through systematic literature review, attendance at conferences and workshops, and interaction with leading experts in the field.
- Provide the trainee with experience that eventually fosters interest in either a clinical career providing evidence-based management of SUD in medical settings or potentially stimulates interest in securing a NIH career development or other grant award to pursue implementation and related research in the field of substance misuse and substance use disorder in subsequent years.
- Provide the trainee with education and experience in effective dissemination of research findings and the implementation/adoption of research in clinical practice. Applicants are
encouraged to develop projects that address or improve upon current gaps in the dissemination of research findings or implementation/adoption of evidence-based treatment practices. The projects will be presented via poster at the AACAP Annual Meeting.
INSTRUCTIONS FOR APPLICATION SUBMISSION
Please submit the following required items to Sarah Hellwege, AACAP’s Deputy Director of Research, Training and Education, at firstname.lastname@example.org by 11:59 pm EST on Wednesday, November 4, 2020.
Note: All letters submitted electronically must contain valid signatures.
Instructions for Application Submission
Candidates cannot have had previous or simultaneous funding from the National Institutes of Health (NIH) or research funding sources. Eligible candidates may not have a training award. Applications that do not adhere to the following guidelines will not be reviewed.
Award recipients are selected through a competitive process. Applicants must submit the following information:
- Completed award application.
- Candidate section, including a personal statement and interest in the substance use field, of no more than two pages (single spaced, no less than 12 pt. font and 1” margins).
- A proposal of no more than five pages (single spaced, no less than 12 pt. font and 1” margins) including:
- Project title and description that includes the following sections: objectives, background, project rationale, project method, and an implementation and dissemination plan.
- A detailed project timeline with tentative dates of all activities for the proposed project.
- A budget and budget justification containing sufficient detail so that each item can be judged separately. Computer related items (e.g., personal computers, printers, modems, etc.) are unlikely to receive budget approval. Salary support will not be provided for the mentor. No indirect costs for the institution will be provided. Typical budget items may include, but are not limited to, honoraria, travel expenses, etc.
- Literature cited page in proposal
- A listing of any current and/or previous award funding.
- The applicant’s current curriculum vitae or biosketch.
- The mentor’s current curriculum vitae or biosketch.
- A letter of support from the residency training director.
- A letter of support from the proposed mentor, of no more than two pages (single spaced, no less than 12 pt. font and 1” margins), including a brief description on how he/she will play a key role in shaping and assisting the candidate in fulfilling the needs of this award.
This award cannot be used to conduct basic or clinical research studies or trials. Awardees are to develop and execute a plan designed to increase their clinical knowledge of the management of SUD and complete a project aimed at improving the dissemination and/or adoption of existing evidence-based SUD treatment research findings. Secondary data analysis of treatment research datasets may be
completed in pursuit of these aims, provided the project proposed is eligible for IRB exemption and has a dissemination/adoption focus but such projects still must address dissemination. Applications proposing non-exempt research involving human subjects that must be reviewed by an IRB under the requirements of the U.S. Department of Health and Human Services (HHS) regulations at 45 CFR part 46 will not be accepted.
Examples of appropriate activities and projects include but are not limited to:
- Reviewing available curricula or training programs; identifying status of education on SUD, especially opioid misuse, OUD diagnosis, and OUD management in various settings; and proposing and conducting activities to improve or increase the adoption of evidence-based practice;
- Identifying best practices or effective strategies or models for SUD education;
- Developing materials that could be used for quality improvement or integration of an evidence-based approach or process in the management of SUD, including OUD, in a medical setting and conducting activities for quality improvement or adoption;
- Identifying training gaps and research findings and/or products developed by NIDA or other federal agencies or professional associations that could bridge gaps, identifying potential partners for effective dissemination of these findings and disseminating them within existing or newly developed communication channels;
- Coursework to strengthen formal training in substance use disorder research and;
- Other activities consistent with the goals of the Dissemination Initiative to accelerate the dissemination of research findings and implementation or adoption of evidence-based SUD treatment in clinical practice.
- Analysis of de-identified data from completed clinical trials such as those found on the NIDA Data Share website (https://datashare.nida.nih.gov/) to inform dissemination or implementation efforts; or from registries such as ACEP Clinical Emergency Data Registry (https://www.acep.org/cedr/) to characterize availability of data on substance use or practice patterns, identify gaps in the provision of evidence-based practices, and/or identify needs for dissemination or implementation.
Please see here for a list of previous awardees and their projects.
RECOMMENDED CLINICAL TOPIC AREAS
Proposals must include components of evidence-based child and adolescent SUD treatment science. Recommended topic areas include:
- Screening and brief intervention for adolescents misusing opioids, marijuana, tobacco, alcohol, and other drugs including prescription medications;
- Smoking cessation for adolescent patients in the medical or behavioral healthcare system;
- Integrating substance abuse treatment for youth with(in) primary care or a medical home;
- Integration or augmentation of electronic health records to include substance misuse and substance use disorders in youth;
- Prescription drug misuse or use disorder in youth;
- Co-occurring disorders in youth; or
- Screening and management of HIV/Hepatitis/STD infections in adolescent patients with substance use disorders.
AACAP will consider additional clinical topics that meet the criteria of direct relevance to child and adolescent substance use disorder treatment science and dissemination. For consideration of a topic not listed above, applicants must contact Carmen J. Thornton, MPH, AACAP Director of Research, Grants, and Workforce at email@example.com to discuss his/her topic before submitting an application.
- Applicants must be enrolled in a psychiatry, child psychiatry, or triple board program and be at the PGY2 level or higher.
- Applicants must be enrolled in a fully accredited general psychiatry or child and adolescent psychiatry clinical research or training program.
- Applicants must have a mentor who has had experience in substance use disorder treatment and/or research. It is preferred that the mentor’s work include children and adolescents. The mentor does not need to be a child psychiatrist by training.
- Candidates must not have any current or previous significant, individual project funding in the field of child and adolescent mental health. Candidates should not have had previous or simultaneous funding from the National Institutes of Health (NIH) or other research funding sources. Eligible candidates will not have a career development award.
- Applicants must either be AACAP members or have a membership application pending (not paid by the award) and agree to submit a proposal for a poster presentation on his or her activities or project for, and attend AACAP's 68th Annual Meeting in Atlanta, Georgia, October 25-30, 2021.
- Applicants must agree to attend the NIDA Clinical Trials Network's Annual Meeting tentatively scheduled for April 26-28, 2021 in Bethesda, MD. Cutting edge research will be presented at the NIDA CTN Annual Meeting and awardees will have the opportunity to network with other clinicians and researchers in the field.
- Applications must be submitted via e-mail to Sarah Hellwege at firstname.lastname@example.org by 11:59 pm EST on Wednesday, November 4, 2020.
- All applicants must be available to attend by teleconference an orientation provided by The Bizzell Group, on behalf of NIDA, on December 18, 2020.
- All applicants are responsible for ensuring their own adherence to all federal research regulations, certifications and assurances. Institutional agreement of acceptance of their role and responsibility for the oversight of the award and proposed activities will be requested through the application process.
- Participants agree to participate in all annual surveys as part of the program evaluation process.
- All award recipients will be required to submit a progress report detailing his/her work in April 2021.
- All award recipients will be required to submit a presentation on his/her project for AACAP’s 68th Annual Meeting.
- All award recipients will be required to submit a final report detailing his/her work in December 2021.
Applications will be reviewed by senior investigators with experience in related work in child and adolescent psychiatry research. Prior to the scientific review process, applications will undergo an administrative review process.
- Administrative Review – Applications will be reviewed for submission of all application materials. Incomplete applications or those that do not adhere to the application guidelines will not be forwarded for further review. Please ensure you meet the eligibility requirements and have submitted all requested application materials before finalizing your application.
- Selection & Review – Applications will undergo a scientific review process by senior child and adolescent psychiatrists with relevant expertise. Applications will be scored by the NIDA-AACAP Resident Training Award Program Selection Committee. The Selection Committee will prepare written reviews and score all applications. The review criteria are as follows:
- Strength of the proposed activities or project plan, including conceptual or clinical framework, or information gathering plan;
- Alignment with the goals of NIDA’s Dissemination Initiative;
- Feasibility of the proposed activities or project to advance scientific knowledge or clinical practice in the field of child and adolescent psychiatry;
- The applicant’s commitment and potential to become a champion of SUD evidence-based treatment in general medical settings and/or career investigator in the SUD field;
- Endorsement, support, and qualifications of the applicant; and
- Strength of commitment and support from the applicant’s host institution.
AACAP reserves the right to cancel the award if terms and conditions are not met. AACAP maintains the right to waive informalities.
All completed applications and attachments must be submitted by
11:59 pm EST on Wednesday, November 4, 2020.
Materials should be sent to Sarah Hellwege at email@example.com
Availability of all awards is contingent upon the receipt of adequate funding.
Last updated: September 2020